XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC [Yahoo! Finance]
Karyopharm Therapeutics Inc. (KPTI)
Last karyopharm therapeutics inc. earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.karyopharm.com/investor-relations
Company Research
Source: Yahoo! Finance
From the second half of 2024 to now, XPOVIO ® was successively approved in Thailand Malaysia and Indonesia , significantly expanding Antengene's commercial presence in APAC. To date, XPOVIO ® has been approved for multiple indications in ten markets across the APAC region. - XPOVIO ® has been approved for health insurance coverage in the mainland of China Taiwan market Australia Singapore and South Korea SHANGHAI and HONG KONG March 5, 2025 /PRNewswire/ -- Antengene Corporation Limited ( "Antengene" , SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that the Indonesia National Agency of Drug and Food Control (BPOM) has approved a New Drug Application (NDA) for XPOVIO ® (selinexor) for three indications: (1) In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma
Show less
Read more
Impact Snapshot
Event Time:
KPTI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KPTI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KPTI alerts
High impacting Karyopharm Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
KPTI
News
- Karyopharm Therapeutics (NASDAQ:KPTI) was given a new $12.00 price target on by analysts at The Goldman Sachs Group, Inc..MarketBeat
- Karyopharm Therapeutics (NASDAQ:KPTI) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- Karyopharm to Participate in Baird's Biotech Discovery SeriesPR Newswire
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare ConferencePR Newswire
KPTI
Earnings
- 11/3/25 - Miss
KPTI
Sec Filings
- 11/24/25 - Form 424B3
- 11/24/25 - Form 424B3
- 11/14/25 - Form SCHEDULE
- KPTI's page on the SEC website